While a direct causal relationship between IL-6 and adverse post-CEA outcomes has not yet been established, accumulating mechanistic and longitudinal evidence indicates that IL-6 plays a pathophysiologically central role in vascular inflammation, endothelial dysfunction, and plaque instability [30]. The gene discussed is IL6; the disease is inflammatory response.